National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for head and neck squamous cell carcinoma. HTA ID: 19051

Pembrolizumab (Keytruda®) is indicated as monotherapy or in combination with platinum and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a combined positive score.

NCPE Assessment Process Complete
Rapid review commissioned 25/11/2019
Rapid review completed 02/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.

 

Full pharmacoeconomic assessment commissioned by the HSE 07/01/2020
Pre-submission consultation with Applicant 24/02/2020
Full submission received from Applicant 28/08/2020
Current status Full HTA submission received from Applicant